

Merck launches Pergoveris Pen for fertility treatment in India

09 August 2021 | News

World's first combined therapy option for recombinant gonadotropins



Merck Specialties, the healthcare business of Merck in India, has launched Pergoveris Pen for advanced infertility treatment in India.

The launch emphasises the company's motive of fulfilling unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency.

The new Pergoveris® Pen allows an improved treatment experience for patients with severe FSH and LH deficiency upon prescription by an IVF specialist.

The novel first-hand version of the Pergoveris Pen is a breakthrough combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment.

In addition, by eliminating the need for mixing, Pergoveris Pen is the world's first combined therapy option for recombinant gonadotropins, demonstrating the efficacy, safety, and combinability of recombinant follitropin alfa with recombinant lutropin alfa, in a single ready to inject device, using Filled-By-Mass Technology, for infertile women in a physiological ratio of 2:1.